Kyle Gowen
Overview
Explore the profile of Kyle Gowen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Weinberg B, Gowen K, Lee T, Ou S, Bristow R, Krill L, et al.
Oncologist
. 2017 Feb;
22(2):152-157.
PMID: 28193735
Background: Metastatic recurrence after treatment for locoregional cancer is a major cause of morbidity and cancer-specific mortality. Distinguishing metastatic recurrence from the development of a second primary cancer has important...
12.
Okimoto R, Breitenbuecher F, Olivas V, Wu W, Gini B, Hofree M, et al.
Nat Genet
. 2016 Nov;
49(1):87-96.
PMID: 27869830
Metastasis is the leading cause of death in people with lung cancer, yet the molecular effectors underlying tumor dissemination remain poorly defined. Through the development of an in vivo spontaneous...
13.
Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang W, et al.
Oncology
. 2016 Oct;
91(6):348-353.
PMID: 27764830
Malignant gastrointestinal neuroectodermal tumor (GNET) is an aggressive rare tumor, primarily occurring in young adults with frequent local-regional metastases and recurrence after local control. The tumor is characterized by the...
14.
Ali S, Hensing T, Schrock A, Allen J, Sanford E, Gowen K, et al.
Oncologist
. 2016 Jun;
21(6):762-70.
PMID: 27245569
Introduction: For patients with non-small cell lung cancer (NSCLC) to benefit from ALK inhibitors, sensitive and specific detection of ALK genomic rearrangements is needed. ALK break-apart fluorescence in situ hybridization...
15.
Zhu V, Upadhyay D, Schrock A, Gowen K, Ali S, Ou S
Lung Cancer
. 2016 May;
97:48-50.
PMID: 27237027
Crizotinib was approved for the treatment of ROS1-rearranged non-small cell lung cancer (NSCLC) patients in the US on 11 March, 2016. Interestingly no one companion diagnostic test (CDx) has been...
16.
Konduri K, Gallant J, Chae Y, Giles F, Gitlitz B, Gowen K, et al.
Cancer Discov
. 2016 Apr;
6(6):601-11.
PMID: 27102076
Unlabelled: Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung...
17.
Klempner S, Gershenhorn B, Tran P, Lee T, Erlander M, Gowen K, et al.
Cancer Discov
. 2016 Apr;
6(6):594-600.
PMID: 27048246
Unlabelled: Neuroendocrine tumors comprise a heterogeneous group of malignancies with a broad spectrum of clinical behavior. Poorly differentiated tumors follow an aggressive course with limited treatment options, and new approaches...
18.
Yakirevich E, Resnick M, Mangray S, Wheeler M, Jackson C, Lombardo K, et al.
Clin Cancer Res
. 2016 Mar;
22(15):3831-40.
PMID: 26933125
Purpose: Chromosomal translocations in the anaplastic lymphoma kinase (ALK) gene have been identified as oncogenic drivers in lung adenocarcinomas and other tumors, recently including rare cases of colorectal carcinoma. We...
19.
Klempner S, Bordoni R, Gowen K, Kaplan H, Stephens P, Ou S, et al.
JAMA Oncol
. 2015 Nov;
2(2):272-4.
PMID: 26562024
No abstract available.
20.
Klempner S, Bazhenova L, Braiteh F, Nikolinakos P, Gowen K, Cervantes C, et al.
Lung Cancer
. 2015 Jul;
89(3):357-9.
PMID: 26187428
Objectives: The gatekeeper mutation T790M mutation is the responsible for the majority of the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small...